Summit Is in Talks for $15 Billion Partnership With AstraZeneca
Save
AstraZeneca Plc is discussing a partnership deal with Summit Therapeutics Inc. in which it could pay as much as $15 billion over time to license a lung-cancer drug, according to people familiar with the matter.
The companies have been holdings talks regarding the potential partnership over Summit's ivonescimab treatment, the people said, asking not to be identified because that matter is private. Summit has also held discussions with other major pharmaceutical firms, the people said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Superyacht recruitment agency opens new office in North Yorkshire
A superyacht recruitment agency has opened a new office. Mycrewagency has set up its latest base at Broughton Hall Sanctuary in the Yorkshire Dales. Known for its personalised approach to connecting crew with superyachts worldwide, the agency says the new Skipton office will support future growth. Michael di Luca, founder of mycrewagency, said: "I believe it's so important to like where you work, not just the role you're doing, but the space you're doing it in. "Opening this office allows us to tap into northern talent and offer more opportunities to the local community. "It would have been easy to follow the crowd and set up in London, but we think it's far more exciting to bring the superyacht industry up north." Michael di Luca, founder of mycrewagency (Image: mycrewagency) Set within 3,000 acres of countryside, the Broughton Hall Sanctuary offers a working environment designed to promote wellness and work-life balance. The office will also serve as the production base for The Superyacht Podcast and will support recruitment, content creation, and crew support. Aligning with mycrewagency's broader goals of sustainability and well-being, the move supports both its own team and the wider yachting industry. As the business continues to grow, the Skipton office is expected to play a key role in developing a close-knit team and strengthening industry connections across the UK and beyond. The company believes that its approach to recruitment is setting a new standard in the superyacht sector by prioritising the well-being and development of both crew and staff. For more information about mycrewagency and current opportunities, visit
Yahoo
44 minutes ago
- Yahoo
Blue bull calf sells for record-breaking £1,000 at Bentham Auction Mart
A 12-week-old Blue bull calf has sold for a record-breaking £1,000 at Bentham Auction Mart. The calf, from Dave Harrison of Wray, led a 'fast' sales day at the event. Other notable sales included Blue bulls from Dave and Rick Barton of Lupton and The Gibbons of St Michaels at £870, Doug Wallbank of Preston at £860, and Ken Polkinghorne of Eldroth and Mark Smith of Gargrave both at £840. Blue heifers fetched up to £710, while Charolais bulls from PM and AM Ward and Sons, Docker, achieved £780 and £880. Angus bulls from Tom Barnes, Kirkby Lonsdale, also achieved prices of £800 and £810. The sale saw a variety of breeds and ages, with younger Blue calves and weanable sorts fetching between £480 and £700.
Yahoo
44 minutes ago
- Yahoo
1 Warren Buffett stock I'm staying well away from
Investors always pay close attention to which stocks Warren Buffett's Berkshire Hathaway is buying – whether or not it's the CEO himself making the decisions. And one stands out to me. Constellation Brands (NYSE:STZ) looks like a classic example of being greedy when others are fearful. But despite the stock being down 31% in the last year, I'm staying away from this one. it's one of the largest US alcohol producers and marketers. And the industry as a whole looks as though it's in a transition phase at the moment. One of the biggest developments is the well-documented shift towards more premium products. This has been happening across beer, wine, and spirits. Constellation Brands isn't oblivious to the ongoing changes. The company has been looking to position its portfolio to align with this trend by divesting some of its lower-priced lines. This looks like a good strategy to me. But there's another ongoing trend that looks more problematic, which involves beer and wine losing market share to spirits. That's a problem for a firm where beer accounts for 85% of overall revenues. Despite growth in some of its premium divisions, the category as a whole being in decline is a big concern. The Berkshire Hathaway investment managers might be seeing something, but I don't know what that is. In the UK, Diageo (LSE:DGE) is also going to contend with challenges to the alcohol industry in general. These include the rise of GLP-1 drugs, which could well weigh on overall demand. I think, however, the FTSE 100 firm has a more attractive portfolio for dealing with these risks. Its sales predominantly come from spirits, with smaller contributions from beer and wine. The strength of Diageo's spirits portfolio is well-documented. But even in its relatively minor wine division, the company is firmly positioned towards the luxury end of the market. Through a joint venture with Moët Hennessy Louis Vuitton, Diageo has access to some of the top champagne names. These include Dom Pérignon, Moët & Chandon, and Veuve Clicquot. Its beer division primarily consists of Guinness, which some analysts have speculated the firm might be looking to sell. But I don't think this would be a particularly welcome development. Guinness sales have been strong recently, underscoring the shift towards premium lines across categories. So I see the division as another reason to be optimistic about Diageo's portfolio. A lot of recent attention has been focused on UK shares trading at lower multiples than their US counterparts. But that's not so obviously the case with Constellation Brands and Diageo. Despite a lower dividend yield and a higher price-to-earnings (P/E) ratio, Constellation Brands trades at a lower free cash flow multiple than its FTSE 100 counterpart. This means that — in one important respect — the stock is cheaper. On balance, however, I think Diageo is in a stronger position to deal with the challenges the alcohol industry is facing. That's why it's the stock I've been buying for my portfolio. The post 1 Warren Buffett stock I'm staying well away from appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Stephen Wright has positions in Berkshire Hathaway and Diageo Plc. The Motley Fool UK has recommended Constellation Brands and Diageo Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
